Determinants of virological response to antiretroviral therapy: Implications for long-term strategies

Clinical Infectious Diseases

Volumn 30, Issue SUPPL. 2, 2000, Pages

  Deeks, S G ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

CONFERENCE PAPER; DRUG ABSORPTION; DRUG EXPOSURE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PREDICTION; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS LOAD;

ANTI-HIV AGENTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

EID: 0034456413     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313855     Document Type: Conference Paper

References (56)

1. Guidelines for the use of antiretroviral agents in HIV infected adults and adolescents
2. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
3. Quantifying residual HIV-replication in patients receiving combination antiretroviral therapy
4. Selection of antiretroviral resistance in the latent reservoir of human immunodeficiency virus type 1 during successful therapy
5. The decay of the latent reservoir of replication competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy
6. Ongoing HIV transmission during HAART
7. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
8. A randomized controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy
9. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine and lamivudine for HIV-1 infection: 100 Week follow-up
10. Prognosis in HIV-infection predicted by the quantity of virus in plasma
11. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
12. - T cell responses associated with control of viremia
13. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
14. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada and Australia Study
15. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection: A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group protocol 241 investigation
16. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
17. Novel four-drug salvage treatment regimens after failure of a protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
18. HIV- 1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
19. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
20. HIV-1 drug resistance in newly infected individuals
21. Reduced antiretroviral drug susceptibility among patients with primary infection
22. Impairment of stavudine (d4T) phosphorylation in patients receiving a combination of zidovudine and d4T (ACTG 290)
23. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
24. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
25. Adherence and effectiveness of protease inhibitors in clinical practice
26. Adherence to combination therapy in AIDS clinical trials
27. Indinavir concentrations and antiviral effect
28. Pharmacodynamics (PD) of indinavir (IDV) in protease-naive HIV-infected patients receiving ZDV and 3TC
29. Ordered accumulation of mutations in HIV-protease confers resistance to ritonavir
30. HIV-protease inhibitors
31. ABT-378/ritonavir therapy in antiretroviral-naive HIV-infected patients for 24 weeks
32. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
33. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients
34. Kinetics of response in lymphoid tissue to antiretroviral therapy of HIV-infection
35. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy
36. Neurological complications of HIV infection
37. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine
38. Indinavir in cerebrospinal fluid of HIV-infected patients
39. Time course of cerebrospinal fluid responses to antiretroviral therapy: Evidence for variable compartmentalization of infection
40. Effect of antiviral treatment on the shedding of HIV-1 in semen
41. Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: Evidence for compartmentalization of HIV-1 between semen and blood
42. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS Clinical Trails Group Protocol 850)
43. Predictors of virologic and clinical responses to indinavir (IDV), ZDV + 3TC or ZDV + 3TC
44. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
45. Predictors of optimal virological response to potent antiretroviral therapy
46. Suppression of plasma viral load below 20 copies/mL is needed to achieve long-term virologic suppression
47. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
48. Patterns of plasma HIV RNA responses in antiretroviral treatment success and failure
49. Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV
50. Human immunodeficiency virus drug therapy and virus load
51. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy
52. Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine and ritonavir therapy
53. CD4 cell count in HIV-1 individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study
54. Sustained CD4 T cell response after virologic failure of protease inhibitor based regimens in HIV infected patients
55. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study